GlassScriptPhysician profile
Paul Hayes
NPI 1487617296
$4,103.81
in general payments reported to CMS, 2019-2025
26 companies · $584 in 2025
The $584 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $579 · 2020: $415 · 2021: $803 · 2022: $787 · 2023: $524 · 2024: $412 · 2025: $584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,520.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $496.36 | 2019-2025 | Jardiance, Synjardy, Spiriva Respimat |
| Bayer Healthcare Pharmaceuticals INC. | $452.64 | 2021-2025 | |
| Abbvie INC. | $421.03 | 2021-2025 | |
| Amgen INC. | $390.23 | 2020-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $387.34 | 2019-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $385.77 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $305.36 | 2019-2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $220.27 | 2019-2022 | |
| Pfizer INC. | $156.92 | 2019-2024 | |
| Glaxosmithkline, LLC. | $153.20 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $139.55 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| E.R. Squibb & Sons, L.L.C. | $104.20 | 2019-2023 | Eliquis |
| Otsuka America Pharmaceutical, INC. | $74.98 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $70.65 | 2021-2023 | Trintellix |
| Xeris Pharmaceuticals, INC. | $51.88 | 2022-2024 | Gvoke Hypopen |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $49.91 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Teva Pharmaceuticals USA, INC. | $43.34 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.74 | 2025 | Caplyta |
| Nestle Healthcare Nutrition INC. | $31.56 | 2020-2022 | |
| Axsome Therapeutics, INC. | $27.45 | 2024 | Auvelity |
| Vanda Pharmaceuticals INC. | $26.63 | 2022 | |
| Sunovion Pharmaceuticals INC. | $26.11 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $15.08 | 2021 | |
| Merck Sharp & Dohme LLC | $13.49 | 2019 | |
| Neurelis, INC. | $13.25 | 2023 | Valtoco |
| Allergan, INC. | $11.87 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Hayes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.